XGEN.DE vs. IDNA

Last updated Apr 2, 2026

Compare and contrast key facts about Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA).

XGEN.DE and IDNA are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. XGEN.DE is a passively managed fund by Xtrackers that tracks the performance of the MSCI ACWI IMI Genomic Innovation Select ESG Screened 100. It was launched on Jul 12, 2022. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. Both XGEN.DE and IDNA are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

XGEN.DE vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a €10,000 investment in Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

XGEN.DE vs. IDNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
XGEN.DE Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C	-4.14%	7.38%	2.95%	-5.84%	-9.98%
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	13.17%	3.35%	5.83%	-10.40%	-26.00%

Different Trading Currencies

XGEN.DE is traded in EUR, while IDNA is traded in USD. To make them comparable, the IDNA values have been converted to EUR using the latest available exchange rates.

Returns By Period

In the year-to-date period, XGEN.DE achieves a -4.14% return, which is significantly lower than IDNA's 13.17% return.

XGEN.DE

• 1D: 2.28%
• 1M: -1.91%
• YTD: -4.14%
• 6M: 5.14%
• 1Y: 11.86%
• 3Y*: 0.68%
• 5Y*: —
• 10Y*: —

IDNA

• 1D: 0.38%
• 1M: -4.57%
• YTD: 13.17%
• 6M: 22.40%
• 1Y: 38.15%
• 3Y*: 6.71%
• 5Y*: -7.60%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

XGEN.DE vs. IDNA - Expense Ratio Comparison

XGEN.DE has a 0.30% expense ratio, which is lower than IDNA's 0.47% expense ratio.

IDNA

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund

XGEN.DE

Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C

Return for Risk

XGEN.DE vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

XGEN.DE

XGEN.DE Risk / Return Rank: 30
XGEN.DE Sharpe Ratio Rank: 28
XGEN.DE Sortino Ratio Rank: 28
XGEN.DE Omega Ratio Rank: 26
XGEN.DE Calmar Ratio Rank: 34
XGEN.DE Martin Ratio Rank: 30

IDNA

IDNA Risk / Return Rank: 85
IDNA Sharpe Ratio Rank: 85
IDNA Sortino Ratio Rank: 86
IDNA Omega Ratio Rank: 74
IDNA Calmar Ratio Rank: 93
IDNA Martin Ratio Rank: 88

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

XGEN.DE vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	XGEN.DE	IDNA	Difference
Sharpe ratio Return per unit of total volatility	0.57	1.38	-0.82
Sortino ratio Return per unit of downside risk	0.89	1.95	-1.06
Omega ratio Gain probability vs. loss probability	1.11	1.24	-0.13
Calmar ratio Return relative to maximum drawdown	0.97	2.52	-1.55
Martin ratio Return relative to average drawdown	2.79	8.26	-5.47
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

XGEN.DE vs. IDNA - Sharpe Ratio Comparison

The current XGEN.DE Sharpe Ratio is 0.57, which is lower than the IDNA Sharpe Ratio of 1.38. The chart below compares the historical Sharpe Ratios of XGEN.DE and IDNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	XGEN.DE	IDNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.57	1.38	-0.82
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.28	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.15	0.10	-0.25

Correlation

The correlation between XGEN.DE and IDNA is 0.57, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

XGEN.DE vs. IDNA - Dividend Comparison

XGEN.DE has not paid dividends to shareholders, while IDNA's dividend yield for the trailing twelve months is around 1.06%.

	TTM	2025	2024	2023	2022	2021	2020	2019
XGEN.DE Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	1.06%	1.18%	0.98%	1.04%	0.54%	0.70%	0.26%	0.80%

Drawdowns

XGEN.DE vs. IDNA - Drawdown Comparison

The maximum XGEN.DE drawdown since its inception was -37.58%, smaller than the maximum IDNA drawdown of -64.58%. Use the drawdown chart below to compare losses from any high point for XGEN.DE and IDNA.

Drawdown Indicators

	XGEN.DE	IDNA	Difference
Max Drawdown Largest peak-to-trough decline	-37.58%	-68.26%	+30.68%
Max Drawdown (1Y) Largest decline over 1 year	-14.88%	-12.11%	-2.77%
Max Drawdown (5Y) Largest decline over 5 years	—	-68.26%	—
Current Drawdown Current decline from peak	-17.22%	-45.05%	+27.83%
Average Drawdown Average peak-to-trough decline	-19.46%	-36.05%	+16.59%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.61%	3.81%	+0.80%

Volatility

XGEN.DE vs. IDNA - Volatility Comparison

The current volatility for Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE) is 6.10%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 8.43%. This indicates that XGEN.DE experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	XGEN.DE	IDNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.10%	8.43%	-2.33%
Volatility (6M) Calculated over the trailing 6-month period	13.02%	17.42%	-4.40%
Volatility (1Y) Calculated over the trailing 1-year period	20.88%	27.79%	-6.91%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	18.50%	27.32%	-8.82%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.50%	29.05%	-10.55%